Drug intelligence / Profile preview

Carbocromen

Development stage: Discontinued
Lead developer: Cassella
Modality: Small Molecules
Administration: Oral

Overview

Carbocromen is a vasodilator used primarily for the treatment of cardiac ischemia, angina pectoris, and hypertension. It was marketed in Germany but has been discontinued due to the risk of arrhythmia development. The drug acts by dilating blood vessels, improving blood flow, particularly in coronary vessels. Its mechanism of action is not fully defined but involves vasodilation, which may be related to phosphodiesterase inhibition.

Brand names: ChromonarIntenkordinIntensainIntercordin
Other names: CarbochromenCarbochromeneCarbocromene

Targets

PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on Carbocromen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carbocromen.

Explore the full profile